Can a Cannabis-Like drug soothe Alzheimer's agitation?

NCT ID NCT04516057

Recruiting now Symptom relief Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether nabilone, a synthetic cannabinoid, can safely reduce agitation in people with Alzheimer's disease. Agitation is common and distressing, with few good treatment options. About 112 participants will receive either nabilone or a placebo for 8 weeks, and researchers will track changes in agitation, behavior, and caregiver stress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease cannabis dependence Psychomotor Agitation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGITATION ALZHEIMER DISEASE

Contacts and locations

Locations

Centre for Addiction and Mental Health
RECRUITING

Toronto, Ontario, Canada
London Health Sciences Centre
RECRUITING

London, Ontario, N6A 5W9, Canada
Ontario Shores Centre for Mental Health Sciences
RECRUITING

Whitby, Ontario, L1N 5S9, Canada
St. Michael's Hospital
RECRUITING

Toronto, Ontario, Canada
Sunnybrook Health Sciences Centre
RECRUITING

Toronto, Ontario, M4N 3M5, Canada
University of Calgary
RECRUITING

Calgary, Alberta, T2N 4N1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.